Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Actuate Therapeutics IncNASDAQ: ACTU

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $1.36M rose 20.6% year over year, behind the +111.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 12.0% from the prior quarter. Over 3 fiscal years it compounded at +109.9% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +20.6% toward the trailing-twelve-month pace of +111.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.36M-12.0% QoQ
Last fiscal yearDec 2025
$6.05M+203.0% YoY
LTMMar 2026
$6.28M+111.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.6%——
1 year+203.0%——
3-year CAGR+109.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.05M USD
Year-over-year change
+203.0%
3-year CAGR
+109.9%

Stock-Based Compensation vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +111.2% is the 2nd highest of 9, against a peer median of -32.7%.
  • Over three fiscal years its annual growth of +109.9% compares with a peer median of -10.7%.
ACTU Competitors
Stock-Based Compensation for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$27.69M USD+218.3%+20.9%—
ALECAlector, Inc.LTM Mar 2026$21.22M USD-43.4%-16.7%115.2%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$9.79M USD-43.4%-24.8%853.3%
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
ACTUActuate Therapeutics IncLTM Mar 2026$6.28M USD+111.2%+109.9%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$3.88M USD-47.0%-22.0%7.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding ACTU) —-32.7%-10.7%115.2%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Depreciation & Amortization0000
Deferred Income Tax0000
Stock-Based Compensation654.07K423.54K2M6.05M
Change in Working Capital1.73M2.57M1.1M(3.05M)
Accounts Receivables0000
Inventory0000
Accounts Payables586.26K1.29M(1.5M)(512.54K)
Other Working Capital1.15M1.28M2.6M(2.53M)
Other Non-Cash Items(20.38K)123.46K2.35M20.25K
Operating Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)
Capital Expenditures0000
Acquisitions (Net)0000
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow0000
Debt Repayment005.5M0
Common Stock Issued0023.96M24.03M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities00(1.93M)(302.83K)
Financing Cash Flow19.26M4.13M27.53M23.72M
Effect of Forex Changes0000
Net Change in Cash1.46M(17.49M)5.68M4.52M
Free Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.